Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.48 |
| ▸ | IL2 | P60568 | 2/20 | 0.48 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.42 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.42 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.42 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.42 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.42 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.42 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.42 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26516537 | 0.89 | FYN (0.53) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL26072857 | 0.83 | TLR8 (0.51) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL29394172 | 0.83 | TLR8 (0.51) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL26516586 | 0.81 | CFTR (0.53) | TLR8TLR7TLR9CFTRMET | |
| SCHEMBL26516612 | 0.81 | MAP4K1 (0.49) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL30360604 | 0.79 | FYN (0.49) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL26120751 | 0.79 | FYN (0.49) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL30360599 | 0.79 | FYN (0.51) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL26516706 | 0.79 | FYN (0.51) | TLR8TLR7TLR9MAP4K1IL2 | |
| SCHEMBL26516625 | 0.76 | TGFBR1 (0.63) | TLR8TLR7TLR9MAP4K1IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200015-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | claimed |
| CN-115956077-A | Substituted heteroaryl compounds as TLR9 inhibitors | 百时美施贵宝公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4200015-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115956077-A | Substituted heteroaryl compounds as TLR9 inhibitors | 百时美施贵宝公司 | 2023-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | TLR8 10/4885TLR7 4/4885TLR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.